Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
81,239actual
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-13 | actual | When the study began enrolling |
| Primary completion | 2025-12-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-31 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chlamydia Trachomatis
Primary outcomes
what the primary-completion date above is the date OFNumber of female participants with documented (confirmed) outpatient or any inpatient of pelvic inflammatory disease (PID)
measured From Year 2008 to Year 2022
Number of female participants with documented confirmed outpatient or any inpatient diagnosis of ectopic pregnancy
measured From Year 2008 to Year 2022
Number of female participants with documented confirmed outpatient or any inpatient diagnosis tubal factor infertility
measured From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of orchitis or epididymitis
measured From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of proctitis
measured From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of prostatitis
measured From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of female/male infertility
measured From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of Urethritis and urethral syndrome
measured From Year 2008 to Year 2022
Time in days from first documented prevalent CT infection to first documented complication/sequelae diagnosis
measured From Year 2008 to Year 2022
Number of male and female participants with confirmed outpatient or any inpatient CT diagnosis at least 30 days after last CT diagnosis of any kind (reinfection)
measured From Year 2008 to Year 2022
Number of CT reinfections/episodes
measured From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of other STI
measured From Year 2008 to Year 2022
Cost incurred from the number of physician contacts (of any specialty)
measured From Year 2008 to Year 2022
Costs incurred from the number of hospital admissions
measured From Year 2008 to Year 2022
Costs incurred for the number of prescriptions filled for any drug
measured From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for any medical aid
measured From Year 2008 to Year 2022
Costs incurred for the number of physician contacts (of any specialty) related to CT or STI-diagnoses.
measured From Year 2008 to Year 2022
Costs incurred for the number of hospital admissions related to CT or STI-diagnoses.
measured From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for CT-related antibiotics, dispensed within 30 days after CT diagnosis
measured From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for medical aids related to CT or STI diagnoses
measured From Year 2008 to Year 2022
Total CT-/STI-unspecific health care costs (inpatient, outpatient, drugs, medical aids)
measured From Year 2008 to Year 2022
CT-/STI-unspecific outpatient costs
measured From Year 2008 to Year 2022
CT-/STI-unspecific inpatient costs
measured From Year 2008 to Year 2022
CT-/STI-unspecific drug cost
measured From Year 2008 to Year 2022
CT-/STI-unspecific medical aid costs
measured From Year 2008 to Year 2022
Outpatient costs that are related to cases with a confirmed CT diagnosis
measured From Year 2008 to Year 2022
Inpatient costs that are related to cases with any CT diagnosis
measured From Year 2008 to Year 2022
Outpatient costs that are related to cases with any confirmed STI diagnosis
measured From Year 2008 to Year 2022
Inpatient costs that are related to cases with any confirmed STI diagnosis
measured From Year 2008 to Year 2022
Costs of potentially CT-relevant antibiotics dispensed up to 30 days after confirmend outpatient or any inpatient CT diagnosis
measured From Year 2008 to Year 2022
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed